Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 144.81

+0.5%

3:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotech Jim who wrote (775)	7/18/2001 11:09:51 AM
From: keokalani'nui	Read Replies (1) of 1834

Jim: The company was asked a question what competing compounds were in human trials. With a laugh--and with great accuracy I suspect--the nbix speaker said he hoped and expected the analysts to have a better idea than he. Then he mentioned only the two, TAK’s melanacortin analogue and Z. It was a meek answer to a throw away question. There was no mention of the age range in this recent study. There was I thought an acknowledgement of future age range-bound studies for elderly and young adults to nail down dosing. I am overweight this one myself. Would appreciate learning if you ever lose your long term enthusiasm for it. Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next